Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1027

In recent years, roboticists and material scientists worldwide have been trying to create artificial systems that resemble human body parts and reproduce their functions. These include artificial skins, protective layers that could also enhance the sensing capabilities of robots.

Researchers at Donghua University in China and the Jülich Centre for Neutron Science (JCNS) in Germany have recently developed a new and highly promising artificial ionic skin based on a self-healable elastic nanomesh, an interwoven structure that resembles human skin. This artificial skin, introduced in a paper published in Nature Communications, is soft, fatigue-free and self-healing.

“As we know, the skin is the largest organ in the human body, which acts as both a protective layer and sensory interface to keep our body healthy and perceptive,” Shengtong Sun, one of the researchers who carried out the study, told TechXplore. “With the rapid development of artificial intelligence and , researchers are currently trying to coat with an ‘artificial skin’ that replicates all the mechanical and sensory properties of human skin, so that they can also perceive the everchanging external environment like us.”

Read more | >

A year back and bodily function improves, and it’s a shot rather than transfusion as needed from other plasma treatments.

Researchers have found that intramuscular injections of plasma concentrate made from human umbilical cord blood improve various health biomarkers and decrease biological age in elderly people [1].

Circulating proteins have a significant impact on our health, and blood plasma transfusion is increasingly used against inflammatory conditions as well as some autoimmune and genetic diseases [2]. Basically, plasma transfusion enables physicians to alter the concentration of interesting molecules in the blood.

In recent years, Michael and Irina Conboy, along with other researchers, have experimented with blood/plasma exchange in the context of longevity [3]. Their continuing research has shown that heterochronic parabiosis (blood exchange between old and young animals), as well as plasma transfusion and even dilution of old plasma [4], alleviate various aspects of aging and decrease biological age as measured by methylation clocks.

Continue reading “Umbilical Plasma Injections Reduce Biological Age in Humans” | >

Glioblastoma is one of the most aggressive types of brain cancer known to man. For many, the chance of survival is often low. However, a new type of brain tumor therapy could help change things for the better. The therapy, which relies on destroying the “power source” of the cancer, has shown considerable success in mice. The scientists are hopeful it will work the same in humans.

The new therapy hopes to destroy the “power source” of glioblastoma tumors. A new study led by Israeli scientists shows that glioblastoma relies on specific brain cells to fuel the growth of its tumors. As a result, scientists began to look at ways to treat cancer by removing those cells instead. The new brain tumor therapy could completely starve out the cancer cells, allowing patients to enter remission.

Normally doctors would use chemotherapy to target the tumors directly. However, by removing brain cells called Astrocytes, scientists found they could starve out glioblastoma tumors in mice. Further, the tumors remained gone for as long as the astrocytes were repressed. And, even when they stopped suppressing, Dr. Lior Mayo, lead author on the study, says that 85 percent of mice stayed in remission.

Read more | >

What We Owe The Future is available now — you can get it wherever you get your (audio)books or here: https://www.amazon.com/What-Owe-Future-William-MacAskill/dp/…atfound-20
This video was sponsored by the author, Will MacAskill. Thanks a lot for the support.

Sources & further reading:
https://sites.google.com/view/sources-civilization-collapse/

At its height, the Roman Empire was home to about 30% of the world’s population, and in many ways the pinnacle of human advancement. Rome became the first city in history to reach one million inhabitants and was a center of technological, legal, and economic progress. An empire impossible to topple, stable and rich and powerful.
Until it wasn’t anymore. First slowly then suddenly, the most powerful civilization on earth collapsed. If this is how it has been over the ages, what about us today? Will we lose our industrial technology, and with that our greatest achievements, from one dollar pizza to smartphones or laser eye surgery? Will all this go away too?

OUR CHANNELS

Continue reading “Is Civilization on the Brink of Collapse?” | >

Did they unlock one of the vital keys to stop aging?

According to a recent National Eye Institute (NEI) study in mice, loss of the protein pigment epithelium-derived factor (PEDF), which protects retinal support cells, may promote age-related changes in the retina.

Age-related retinal diseases, such as age-related macular degeneration (AMD), can cause blindness since the retina is the light-sensitive tissue at the back of the eye. The new information could help develop medicines to stop AMD and other aging conditions of the retina. The research was published in the International Journal of Molecular Sciences. NEI is part of the National Institutes of Health.

“People have called PEDF the ‘youth’ protein because it is abundant in young retinas, but it declines during aging,” said Patricia Becerra, Ph.D., chief of NEI’s Section of Protein Structure and Function and senior author of the study. “This study showed for the first time that just removing PEDF leads to a host of gene changes that mimic aging in the retina.”

Continue reading “Scientists Find That the Loss of a “Youth” Protein Could Drive Aging” | >

Dr Vittorio Sabastiano explains the possibilities on resetting the age of any cell type in the near future in this clip.

Dr. Vittorio Sebastiano is an Assistant Professor in the Department of Obstetrics and Gynecology at Stanford School of Medicine. His lab has established a new technology named ERA (Epigenetic Reprogramming of Aging), which repurposes the conceptual idea of reprogramming, with the goal to promote epigenetic rejuvenation of adult cells leaving their identity untouched. This new technology was patented and is being implemented by Turn Biotechnologies, of which Dr. Sebastiano is co-founder and Chair of the Scientific Advisory Board.

In 2009, Dr. Sebastiano completed a postdoctoral fellowship at the laboratory of Dr. Marius Wernig at Stanford University, where he implemented the newly discovered iPSC technology and was among the first to demonstrate that iPSCs can be efficiently derived, genetically modified, and implemented for cell therapy in genetic diseases (Sebastiano et al., 2014, Science Translational Medicine).
Dr. Sebastiano completed his undergraduate and graduate studies at the University of Pavia, Italy, where he studied murine germ cells and preimplantation development and where he pioneered cellular reprogramming by Somatic Cell Nuclear Transfer. He joined the Max Planck Institute for Molecular Biomedicine as a postdoctoral fellow under the mentorship of Dr. Hans Robert Schöler, where he continued his research on cellular reprograming, germ cells biology, and embryonic development.

DISCLAIMER: Please note that none of the information in this video constitutes health advice or should be substituted in lieu of professional guidance. The video content is purely for informational purposes.

Continue reading “FOREVER YOUNG — The Peter Pan Case | Dr Vittorio Sabastiano Interview Clips” | >

An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a study in mice from researchers at Washington University School of Medicine in St. Louis, Grenoble Alpes University in Grenoble, France, and The University of Texas MD Anderson Cancer Center in Houston.

One of the drugs, cyclophosphamide, is an outdated chemotherapy drug once used to treat small cell lung cancer. It was displaced in favor of platinum-based drugs in the 1980s. Both kinds of drugs work at first but falter after a few months as the cancer develops resistance. Platinum-based drugs became the standard of care mainly because they cause lesser side effects, but they have not substantially improved prognosis. Today, the typical patient survives less than a year and a half after diagnosis.

In this study, however, researchers showed that small cell lung cancer cells resist cyclophosphamide by activating a specific repair process, and demonstrated that throwing a wrench into the repair process makes the drug much more effective, at least in mice. The findings, available online in Cancer Discovery, suggest a pathway to better therapies for one of the least treatable forms of cancer.

Read more | >